abstract |
The present invention relates to specific dosages and dosing schedules for using 1,2,4-oxadiazole benzoic acid compounds to treat or prevent nonsense mutation-related diseases. In particular, the invention relates to the use of 3- [5- (2-fluoro-phenyl)-[1,2,4] oxadiazol-3-yl] -benzoic acid in a mammal having a nonsense mutation-related disease Related to specific doses and dosing schedules. [Selection] Figure 1 |